A new case study from Cardinal Health highlights the value of RWE (real world evidence) in clinical trials. This RWE data helped a biopharmaceutical company speed up the FDA approval process for their product.
“See how experts from our Real-World Evidence and Insights team helped a biopharmaceutical company generate a RWE control arm to supplement phase 2 experimental data. Through these efforts, the company was able to successfully secure FDA accelerated approval and a competitive market entrance.” Read the case study here.
(Source: Cardinal Health, 2021)